Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)

Trial Profile

Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
  • Indications Hodgkin's disease; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms POPSTAR
  • Sponsors GSK

Most Recent Events

  • 27 Feb 2025 Planned End Date changed from 12 Nov 2030 to 2 Jan 2032.
  • 27 Feb 2025 Planned primary completion date changed from 17 Aug 2028 to 5 Oct 2029.
  • 27 Feb 2025 Planned initiation date changed from 31 Dec 2024 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top